Molecular Characterization and Epidemiology of Carbapenem-Resistant Enterobacteriaceae Isolated from Pediatric Patients in Guangzhou, Southern China

Table 1

In vitro activities of antimicrobial agents against CRE.

Antimicrobials	All isolates (n = 54)			blaNDM + strains (n = 17)			blaIMP + strains (n = 13)			Comparison between NDM and IMP
	R(%)	MIC50	MIC90	R(%)	MIC50	MIC90	R(%)	MIC50	MIC90	χ^2	value
Piperacillin/tazobactam	94.4	≥128	≥128	100	≥128	≥128	92.3	≥128	≥128	—	0.245
Cefoperazone/sulbactam	94.4	≥64	≥64	100	≥64	≥64	92.3	≥64	≥64	—	—
Ceftazidime	94.4	≥64	≥64	100	≥64	≥64	76.9	≥64	≥64	—	—
Cefepime	94.4	≥32	≥32	100	≥32	≥32	76.9	≥32	≥32	—
Aztreonam	72.2	≥64	≥64	76.5	≥64	≥64	69.2	≥64	≥64
Imipenem	96.3	≥16	≥16	100	≥16	≥16	100	≥16	≥16	—	—
Meropenem	94.4	≥16	≥16	100	≥16	≥16	84.6	≥16	≥16	—	—
Tobramycin	29.6	≤1	8	11.8	≤1	8	53.8	8	8	6.212	0.013
Amikacin	5.6	≤2	≤2	0	≤2	≤2	0	≤2	≤2	—	—
Levoacinine	16.7	1	1	11.8	≤0.12	≥8	0	1	4	—	—
Ciprocininen	14.8	0.5	1	11.8	≤0.25	≥4	7.7	0.5	1	—	—
Sulfamethoxazole/trimethoprim	33.3	2/38	≥16/30	70.6	≥16/30	≥16/30	46.2	≤1/19	≥16/30	3.096	0.078
Colistin	0	≤0.5	≤0.5	0	≤0.5	≤0.5	0	≤0.5	≤0.5	—	—
Doxycycline	77.8	≥16	≥16	94.1	≥16	≥16	53.8	≥16	≥16	6.679	0.01
Minocycline	85.2	≥16	≥16	94.1	≥16	≥16	69.2	8	≥16	3.285	0.07
Tigecycline	9.3	1	≥8	0	1	2	15.4	1	2	—	—